Shin Nippon Biomedical Laboratories Ltd operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shin Nippon Biomedical Laboratories Ltd with three other
companies in this sector in Japan:
Morishita Jintan Co., Ltd.
sales of 10.09 billion Japanese Yen [US$92.73 million]
of which 74%
was Health Care Business),
(7.22 billion Japanese Yen [US$66.32 million]
of which 100%
was Alliance), and
Linical Company Limited
(11.31 billion Japanese Yen [US$103.97 million]
of which 92%
was Cro Business).
During the year ended March of 2019, sales at
Shin Nippon Biomedical Laboratories Ltd were ¥15.66 billion (US$143.90 million).
decrease of 5.7%
versus 2018, when the company's sales were ¥16.60 billion.
The sales level in 2019 was fairly close to the level five years ago: in 2014, Shin Nippon Biomedical Laboratories Ltd had sales
of ¥16.93 billion.
Contributing to the drop in overall sales was the 70.9% decline
in Translational Research Project, from ¥39.69 million to ¥11.54 million.
There were also decreases in sales in
Pre-Clinical Business (down 1.3% to ¥13.72 billion)
Clinical Business (down 43.7% to ¥981.29 million)
However, these declines were partially offset by the increase in sales of
Police Medi (up 2.1% to ¥931.27 million)
Other (up 768.8% to ¥17.33 million)